Cargando…

A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

BACKGROUND: Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time. We aimed to compare the trajectories of QoL between amyloid-positive and amylo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mank, Arenda, Rijnhart, Judith J. M., van Maurik, Ingrid S., Jönsson, Linus, Handels, Ron, Bakker, Els D., Teunissen, Charlotte E., van Berckel, Bart N. M., van Harten, Argonde C., Berkhof, Johannes, van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476356/ https://www.ncbi.nlm.nih.gov/pubmed/36109800 http://dx.doi.org/10.1186/s13195-022-01075-8

Ejemplares similares

Life satisfaction across the entire trajectory of Alzheimer's disease: A mediation analysis
por: Mank, Arenda, et al.
Publicado: (2022)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Determinants of informal care time, distress, depression, and quality of life in care partners along the trajectory of Alzheimer's disease
por: Mank, Arenda, et al.
Publicado: (2023)

Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?
por: Mank, Arenda, et al.
Publicado: (2021)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline
por: van Maurik, Ingrid S., et al.
Publicado: (2020)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Longitudinal change in ATN biomarkers in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Steeper memory decline after COVID-19 lockdown measures
por: Bakker, Els D., et al.
Publicado: (2023)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2016)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Rationale and design of the ABOARD project (A Personalized Medicine Approach for Alzheimer's Disease)
por: Dreves, Maria A. E., et al.
Publicado: (2023)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
por: Eikelboom, Willem S., et al.
Publicado: (2021)

Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals
por: Hendriksen, Heleen M. A., et al.
Publicado: (2023)

Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum
por: Dubbelman, Mark A., et al.
Publicado: (2020)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics
por: Fruijtier, Agnetha D., et al.
Publicado: (2019)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment
por: van Maurik, I. S., et al.
Publicado: (2023)

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
por: de Wilde, Arno, et al.
Publicado: (2017)

Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease
por: Scheltens, Nienke M.E., et al.
Publicado: (2019)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
por: Babapour Mofrad, Rosha, et al.
Publicado: (2021)

Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface
por: Vermunt, Lisa, et al.
Publicado: (2022)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease
por: van Maurik, Ingrid S, et al.
Publicado: (2019)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l08fv9mo0agk4fup6fsv8sfflh